Related Experiment Video
Updated: Aug 13, 2026
05:08
Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
Published on: October 3, 2019
Changes in the beta-adrenergic system due to beta-adrenergic therapy: clinical consequences
European Journal of Respiratory Diseases. Supplement
|January 1, 1984
Summary
Continuous beta-agonist therapy may desensitize white blood cells, but lung function in asthma patients doesn't show this effect. This review explores the discrepancy and its clinical implications for asthma treatment.
Area of Science:
- Pharmacology
- Respiratory Medicine
- Immunology
Background:
- Hormonal agonists can cause desensitization with continued exposure.
- Beta-adrenergic therapy has been shown to reduce beta-adrenergic response and receptor numbers in white blood cells.
- White blood cells have numerous beta 2-adrenergic receptors, suggesting potential issues with continuous beta-agonist use in asthma.
Purpose of the Study:
- To review the discrepancy between white blood cell desensitization and lung function measurements in asthmatic patients undergoing continuous beta-adrenergic therapy.
- To consider the clinical consequences of this observed discrepancy.
Main Methods:
- Literature review of studies investigating beta-adrenergic therapy, desensitization, white blood cell response, and lung function in asthma.
- Analysis of conflicting data between cellular and clinical outcomes.
Main Results:
- Studies on white blood cells show reduced beta-adrenergic response and receptor binding sites with continuous beta-agonist exposure.
- Lung function measurements in asthmatic patients on continuous beta-agonist therapy have not consistently demonstrated desensitization.
Conclusions:
- A significant discrepancy exists between in vitro findings on white blood cells and in vivo clinical observations of lung function during continuous beta-adrenergic therapy in asthma.
- The clinical relevance of white blood cell desensitization for long-term asthma management remains unclear and warrants further investigation.
Related Concept Videos
01:26Adrenergic Receptors: β Subtype
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
01:30Adrenergic Agonists: Therapeutic Uses
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...